A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Alectinib (Primary) ; Cobimetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Aug 2017 Planned End Date changed from 30 Jun 2020 to 30 Aug 2020.
- 09 Aug 2017 Planned primary completion date changed from 30 Jun 2019 to 30 Aug 2019.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.